CXCR1/2 Inhibitors and MDSC, A Promising Future Immunotherapy Target
CXCR1/2 inhibitors have been shown to target myeloid-derived suppressor cells (MDSCs), which are immune cells that suppress the anti-tumor immune response and promote tumor growth. CXCR1/2 is involved in the recruitment of MDSCs to the tumor microenvironment, and inhibiting CXCR1/2 can prevent the recruitment of MDSCs, potentially enhancing the anti-tumor immune response.
Preclinical studies have shown that CXCR1/2 inhibitors can reduce the number of MDSCs in the tumor microenvironment and enhance the effectiveness of cancer immunotherapy in animal models. For example, combining a CXCR1/2 inhibitor with an immune checkpoint inhibitor has been shown to reduce the number of MDSCs in the tumor microenvironment and enhance anti-tumor immunity in preclinical models of melanoma.
Several clinical trials are currently underway to evaluate the safety and efficacy of CXCR1/2 inhibitors, including SX-682, in cancer patients. The goal of these trials is to determine whether targeting CXCR1/2 can reduce the number of MDSCs in the tumor microenvironment and enhance the anti-tumor immune response. If successful, CXCR1/2 inhibitors could provide a new treatment option for cancer patients who do not respond to existing immunotherapies.